These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 35279473)
21. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Doig KD; Fellowes AP; Fox SB Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098 [TBL] [Abstract][Full Text] [Related]
22. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794 [TBL] [Abstract][Full Text] [Related]
23. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551 [TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449 [TBL] [Abstract][Full Text] [Related]
25. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. Lee EK; Matulonis UA Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489 [TBL] [Abstract][Full Text] [Related]
26. [Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey]. Quesada S; Solassol J; Ray-Coquard I; Fabbro M Bull Cancer; 2023 Apr; 110(4):371-381. PubMed ID: 36863920 [TBL] [Abstract][Full Text] [Related]
27. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940 [TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303 [TBL] [Abstract][Full Text] [Related]
29. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when? Vanacker H; Romeo C; Ray-Coquard I Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830 [TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Mukhopadhyay A; Plummer ER; Elattar A; Soohoo S; Uzir B; Quinn JE; McCluggage WG; Maxwell P; Aneke H; Curtin NJ; Edmondson RJ Cancer Res; 2012 Nov; 72(22):5675-82. PubMed ID: 23066035 [TBL] [Abstract][Full Text] [Related]
31. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51. Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845 [TBL] [Abstract][Full Text] [Related]
32. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896 [TBL] [Abstract][Full Text] [Related]
33. Appropriate Selection of PARP Inhibitors in Ovarian Cancer. Smith M; Pothuri B Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195 [TBL] [Abstract][Full Text] [Related]
36. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Washington CR; Moore KN Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509 [TBL] [Abstract][Full Text] [Related]
37. Low testing rates and high Syed N; Chintakuntlawar AV; Vilasini D; Al Salami AM; Al Hasan R; Afrooz I; Uttam Chandani K; Chandani AU; Chehal A World J Clin Oncol; 2024 Jul; 15(7):848-858. PubMed ID: 39071455 [TBL] [Abstract][Full Text] [Related]
38. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281 [TBL] [Abstract][Full Text] [Related]
39. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473 [TBL] [Abstract][Full Text] [Related]
40. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency. Yuan P; Ma N; Xu B Med Res Rev; 2024 Nov; 44(6):2774-2792. PubMed ID: 38922930 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]